Targeting PRMT5: A Novel Way to Conquer MTAP-Deleted Unresectable/Metastatic Solid Tumors Dr Pasi Jänne, Dr Konstantinos Leventakos

https://www.medscape.com/viewarticle/1002167?src=0_nl_sms_0&uac=148436CN In this video, Drs Pasi Jänne (Dana-Farber Cancer Institute) and Konstantinos Leventakos (Mayo Clinic, Minnesota) address key clinical questions, including: • What is MTAP deletion and how does it create a dependency on PRMT5? • How do MTA-cooperative PRMT5 inhibitors work to exploit MTAP deletion? • What do current trials reveal about the efficacy and safety of MTA-cooperative PRMT5is?